[1]GROUP OLOE. The Oxford levels of evidence 2[EB/OL].(2022-10-14)[2023-01-10]. https://www.cebm.net/.
[2]GUYATT G,SACKETT D,TAYLOR D W,et al. Determining optimal therapy--randomized trials in individual patients[J]. N Engl J Med,1986,314(14):889-892.
[3]MIRZA RD,PUNJA S,VOHRA S,et al. The history and development of N-of-1 trials[J]. J R Soc Med,2017,110(8):330-340.
[4]NIKLES C J,GLASZIOU P P,DEL M C,et al. N of 1 trials. Practical tools for medication management[J]. Aust Fam Physician,2000,29(11):1108-1112.
[5]KRAVITZ R L,DUAN N. Design and Implementation of N-of-1 trials:a user’s guide[M]. Rockville:AHRQ Publication,2014.
[6]GUYATT G,JAESCHKE R,MCGINN T. Users’ guides to the medical literature:a manual for evidence-based clinical practice 2nd ed[M]. Columbus:McGraw-Hill,2008.
[7]王辉,翟静波,陈静,等. 单病例随机对照试验的设计和实施要点[J]. 中国循证医学杂志,2017,17(3):364-368.
[8]VOHRA S,SHAMSEER L,SAMPSON M,et al. CONSORT extension for reporting N-of-1 trials(CENT) 2015 statement[J/OL]. BMJ,2015,350:h1738[2023-01-10]. https://www.bmj.com/content/350/bmj.h1738.
[9]翟静波,商洪才,李江,等. 单病例随机对照试验的统计分析方法[J]. 中国循证医学杂志,2017,17(4):494-496.
[10]HERRETT E,WILLIAMSON E,BRACK K,et al. Statin treatment and muscle symptoms:series of randomised,placebo controlled n-of-1 trials[J/OL]. BMJ,2021,372:n135[2023-01-10]. https://doi.org/10.1136/bmj.n135.
[11]LI J,GAO W,PUNJA S,et al. Reporting quality of N-of-1 trials published between 1985 and 2013:a systematic review[J/OL]. J Clin Epidemiol,2016,76:57-64[2023-01-10]. https://doi.org/10.1016/j.jclinepi.2015.11.016.
[12]SHAMSEER L,SAMPSON M,BUKUTU C,et al. CONSORT extension for reporting N-of-1 trials(CENT) 2015:explanation and elaboration[J/OL]. BMJ,2015,350:h1793[2023-01-10]. https://doi.org/10.1136/bmj.h1793.
[13]PORCINO A J,SHAMSEER L,CHAN A W,et al. SPIRIT extension and elaboration for n-of-1 trials:SPENT 2019 checklist[J/OL]. BMJ,2020,368:m122[2023-01-10]. https://doi.org/10.1136/bmj.m122.